Please login to the form below
chronic cough
This page shows the latest chronic cough news and features for those working in and with pharma, biotech and healthcare.
Menlo slumps as itching drug fails mid-stage trial
Menlo Therapeutics has said its phase 2 trial of serlopitant in chronic itching (pruritus) is a bust, blaming the result on a high placebo response rate. ... like rival Vanda Therapeutics did with its rival NK1 drug tradipitant this week – as well as
Latest news
-
Bayer extends alliance with Evotec in women’s health
has been pursued for the treatment of chronic cough.
-
Merck says Afferent’s chronic cough drug clears mid-stage trial
MK-7264 reduces coughs per hour by 37%. Merck &Co's purchase of Afferent Pharma last year was all about a candidate drug for chronic cough - so it will be celebrating ... P2X3 receptors are thought to become over-activated in chronic cough, playing a
-
Merck buys cough drug developer Afferent for $1.25bn
Merck &Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate for chronic cough to its pipeline. ... In a statement Merck's R&F head Roger Perlmutter said chronic cough represents "an area of significant unmet
-
BMS takes option to buy fibrosis firm Galecto
It takes the form of a progressive scarring of the lungs, leading to shortness of breath, cough and - in extreme cases - can lead to fatal complications such as heart failure. ... Genoa Pharmaceuticals has an inhaled version of pirfenidone in phase III
-
Pharma firms open up drug libraries to UK researchers
For example, clinical trials are now underway in Manchester to see whether an AZ drug designed originally to treat gastro-oesophageal reflux disease can be used to treat chronic cough.
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch June 2016
AF-219, a selective, non-narcotic, oral P2X3 antagonist, is currently in a phase 2b trial for the treatment of refractory, chronic cough and in a phase 2 trial in idiopathic ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
- Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- Novo Nordisk growth takes a hit with China deal
- Innovation in a digital context is not about technology – it’s about people
PMHub
Genetic Digital
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
